Skip to main content

Thirteen-Member Proteomics Innovation Network Debuts This Week


Thirteen proteomics service and product providers have formed a new organization this week that aims to provide "sample to discovery" solutions for all stages of proteomics research, and to address "critical unmet needs in biomarker and drug target discovery, personalized medicine, drug profiling, and selective reaction monitoring," it said in a statement.

The group, called Proteomics Innovation Network, comprises: ProFACT Proteomics, Norton Scientific, Eprogen, Neolomed Biosciences, Focus Proteomics, New England Peptide, Ontario Cancer Biomarker Network, Innova Proteomics, Dualsystems Biotech, NewLibertyProteomics, Horluce BioConsulting, the Australian Proteome Analysis Facility, and Covaris.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.